Hrt Financial LP Aerie Pharmaceuticals Inc Transaction History

Hrt Financial LP

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 12, 2022	SELL	$4.95 - $9.16 $478,689 - $885,817	-96,705 Closed	0 $0
Q1 2022 May 16, 2022	SELL	$5.64 - $9.8 $297,510 - $516,950	-52,750 Reduced 35.29%	96,705 $880,000
Q4 2021 Feb 14, 2022	BUY	$7.02 - $13.33 $1.05 Million - $1.99 Million	149,455 New	149,455 $1.05 Million
Q2 2021 Aug 16, 2021	SELL	$15.16 - $18.97 $153,707 - $192,336	-10,139 Closed	0 $0
Q1 2021 May 17, 2021	BUY	$13.12 - $20.9 $133,023 - $211,905	10,139 New	10,139 $181,000
Q3 2020 Nov 13, 2020	SELL	$10.46 - $14.46 $202,411 - $279,815	-19,351 Closed	0 $0
Q2 2020 Aug 14, 2020	BUY	$12.0 - $16.13 $232,212 - $312,131	19,351 New	19,351 $285,000

2.4M

Ticker AERI
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 49,390,500
Description
Aerie Pharmaceuticals, Inc., a pharmaceutical company, focuses on the discovery, development, and commercialization of ophthalmic therapies for open-angle glaucoma, dry eye, diabetic macular edema, and wet age-related macular degeneration in the United States. Its products include Rhopressa, a once-daily eye drop to reduce elevated intraocular p...

Get notified when there are updates to the investment portfolio of Hrt Financial LP, based on Form 13F filings with the SEC.

Stay updated on Hrt Financial LP with notifications on news.